AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Solute carrier family 2, facilitated glucose transporter member 9 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Solute carrier family 2, facilitated glucose transporter member 9 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Solute carrier family 2, facilitated glucose transporter member 9, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Solute carrier family 2, facilitated glucose transporter member 9. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Solute carrier family 2, facilitated glucose transporter member 9. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Solute carrier family 2, facilitated glucose transporter member 9 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Solute carrier family 2, facilitated glucose transporter member 9
partner:
Reaxense
upacc:
Q9NRM0
UPID:
GTR9_HUMAN
Alternative names:
Glucose transporter type 9; Urate transporter
Alternative UPACC:
Q9NRM0; Q0VGC4; Q4W5D1; Q8WV30; Q96P00
Background:
Solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9), also known as Glucose transporter type 9 and Urate transporter, plays a pivotal role in urate reabsorption in proximal renal tubules. It exhibits a high-capacity for urate transport, significantly outpacing its glucose transport activity. Additionally, SLC2A9 has a minor role in transporting fructose and adenine, but not galactose or other nucleobases.
Therapeutic significance:
SLC2A9's dysfunction is linked to Hypouricemia renal 2, a disorder marked by impaired uric acid reabsorption leading to high urinary urate excretion. This condition can result in exercise-induced acute renal failure, chronic renal dysfunction, and nephrolithiasis. Understanding the role of SLC2A9 could open doors to potential therapeutic strategies for managing these renal complications.
